ScholarLens Back to search
2014•Australian pharmacistRequires access

Canagliflozin: A new SGLT2 inhibitor for type 2 diabetes

Mark Kennedy

Open publisher page 0 citations

Abstract

About 85% of the 1.7 million Australians living with diabetes have type 2 diabetes. Up to half of cases of type 2 diabetes are undiagnosed. Of those diagnosed, data suggest only about half reach guideline targets for glycaemic control (HbA1c <7% or 53 mmol/mol). This is a concern as poor glycaemic control is a well established risk factor for long-term complications.

About this research paper

What this paper is about

About 85% of the 1.7 million Australians living with diabetes have type 2 diabetes. Up to half of cases of type 2 diabetes are undiagnosed. Of those diagnosed, data suggest only about half reach guideline targets for glycaemic control (HbA1c <7% or 53 mmol/mol). This is a concern as poor glycaemic control is a well established risk factor for long-term complications.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

About 85% of the 1.7 million Australians living with diabetes have type 2 diabetes. Up to half of cases of type 2 diabetes are undiagnosed. Of those diagnosed, data suggest only about half reach guideline targets for glycaemic control (HbA1c <7% or 53 mmol/mol). This is a concern as poor glycaemic control is a well established risk factor for long-term complications.

Key concepts: Canagliflozin, Guideline, Medicine, Type 2 diabetes, Diabetes mellitus, Intensive care medicine, Internal medicine, Pediatrics

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Canagliflozin: A new SGLT2 inhibitor for type 2 diabetes — Research Paper | ScholarLens